CRSP vs KRRO
CRSP: CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and beta thalassemia, plus a pipeline of in vivo and cell therapy programs. KRRO: Korro Bio is a clinical-stage biotechnology company developing genetic medicines via a proprietary oligonucleotide platform, currently focused on treating alpha-1 antitrypsin deficiency.
Side-by-side fundamentals
| Metric | CRSP | KRRO | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $46.73 | $10.72 | |
| Market cap as of 2026-07-30 | $4.5B | $146M | |
| PEG as of 2026-07-30 | -0.20 | -0.04 | CRSP lower |
| Net margin as of 2026-07-30 | -13856.5% | -1834.5% | KRRO higher |
| Gross margin as of 2026-07-30 | n/a | +44.7% | |
| Operating margin as of 2026-07-30 | -15754.2% | -1906.4% | KRRO higher |
| ROE as of 2026-07-30 | -30.9% | -117.9% | CRSP higher |
| ROA as of 2026-07-30 | -24.5% | -71.0% | CRSP higher |
| Debt / equity as of 2026-07-30 | 0.32 | 0.00 | KRRO lower |
| Revenue growth (YoY) as of 2026-07-30 | -89.1% | -20.3% | KRRO higher |
| Revenue CAGR (3y) SEC XBRL | +43.1% | n/a | |
| Beta as of 2026-07-30 | 1.77 | 3.07 | |
| 1-year return as of 2026-07-27 close | -27.8% | -33.0% | CRSP higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.